CTI BioPharma Corp  

(Public, NASDAQ:CTIC)   Watch this stock  
Find more results for CTIC
2.24
+0.05 (2.28%)
Real-time:   11:30AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.19 - 2.24
52 week 2.00 - 4.22
Open 2.19
Vol / Avg. 414,465.00/1.49M
Mkt cap 389.37M
P/E     -
Div/yield     -
EPS -0.28
Shares 177.00M
Beta 1.05
Inst. own 27%
Mar 2, 2015
Q4 2014 CTi Biopharma Corp Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Dec 3, 2014
CTi Biopharma Corp at Piper Jaffray Healthcare Conference - Webcast
Nov 19, 2014
CTi Biopharma Corp at Jefferies Global Healthcare Conference - London - Webcast
Oct 29, 2014
Q3 2014 CTi Biopharma Corp Earnings Call - Webcast
Oct 29, 2014
Q3 2014 CTi Biopharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 11.03% -125.58%
Operating margin 18.90% -119.75%
EBITD margin - -114.69%
Return on average assets 28.24% -52.02%
Return on average equity 130.24% -124.54%
Employees 106 -
CDP Score - -

Address

Suite 600 3101 Western Avenue
SEATTLE, WA 98121
United States - Map
+1-206-2827100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer. The Company�s product Pixantrone (PIXUVRI) is a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphomas. The Company�s pipeline products are Tosedostat, an oral aminopeptidase inhibitor that has demonstrated significant responses in patients with Acute Myeloid Leukemia (AML); Paclitaxel Poliglumex (Opaxio), a biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity; and Pacritinib, is an oral tyrosine kinase inhibitor with dual activity against Janus Kinase 2, or JAK2, and FMS-like tyrosine kinase (also known as FLT3), which demonstrated meaningful clinical benefit and good tolerability in myelofibrosis patients in Phase 2 clinical trials.

Officers and directors

Phillip M. Nudelman Ph.D. Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
James A. Bianco M.D. President, Chief Executive Officer, Director
Age: 57
Bio & Compensation  - Reuters
Louis A. Bianco Executive Vice President, Finance and Administration, and Chief Governance Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Jack W. Singer M.D. Interim Chief Medical Officer, Executive Vice President, Global Medical Affairs and Translational Medicine, and Chief Compliance Officer.
Age: 71
Bio & Compensation  - Reuters
Matthew J. Plunkett Ph.D. Executive Vice President, Corporate Development
Age: 42
Bio & Compensation  - Reuters
Nancy L. Boman Ph.D. Senior Vice President of Clinical Development and Regulatory Affairs
Bio & Compensation  - Reuters
Monique M. Greer Senior Vice President of Corporate Communications and Investor Relations
Age: 47
Bio & Compensation  - Reuters
Karen Ignagni Director
Age: 60
Bio & Compensation  - Reuters
John H. Bauer Independent Director
Age: 73
Bio & Compensation  - Reuters
Vartan Gregorian Ph.D. Independent Director
Age: 79
Bio & Compensation  - Reuters